Keenova Publishes New XIAFLEX Data in Peyronie’s Disease
Dublin, Ireland, August 3, 2026 Keenova Therapeutics plc announced the publication of a new manuscript evaluating XIAFLEX® (collagenase clostridium...
FDA guidance
Advertisement
Acurx Gains FDA Guidance for Ibezapolstat Phase 3 Program
Staten Island, New York, August 3, 2026 Acurx Pharmaceuticals, Inc. announced further regulatory guidance from the U.S. Food and...
Polyrizon Advances NASARIX™ Toward First-in-Human Trial
RAANANA, Israel, July 2, 2026 Polyrizon Ltd. announced the successful completion of its NASARIX™ biocompatibility evaluation program, marking an...
FDA Releases Pregnancy Safety Guidance for Drugs and Biologics
WASHINGTON, D.C., United States – May 8, 2026 The U.S. Food and Drug Administration announced the release of a...
Advertisement
